| Document |
Document Title |
|
WO/2013/181332A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donor...
|
|
WO/2013/164513A1 |
The invention relates to derivatives of tamoxifen and to the uses thereof as a pharmaceutical composition in the treatment of diseases associated with activation of estrogen signaling, as a tool for the identification of target molecules...
|
|
WO/2013/144228A1 |
The present invention relates to pesticidal methods for the use and application of substituted heterocyclic compounds of formula (I) and the stereoisomers, salts, tautomers and N-oxides thereof and to compositions comprising the same. Th...
|
|
WO/2013/144180A1 |
This invention relates to certain heteroaryl compounds for use as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of helminth infections and the treatment of parasitosis ca...
|
|
WO/2013/140331A1 |
The present invention relates in general terms to a variously substituted 1, 2, 4-oxadiazol derivative, a process for their preparation, and use thereof as an intermediate in the preparation of indolic alkaloids, including phidianidine B...
|
|
WO/2013/139020A1 |
Methods of forming a liquid crystal blue phase from composite materials having a chiral nematic liquid crystal host and a bent-shape molecule are described. The stable temperature range of the liquid crystal blue phase may be improved by...
|
|
WO/2013/134061A1 |
The present invention provides novel phenicol derivatives of formula I, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.
|
|
WO/2013/124228A1 |
The invention relates to suifin- and sulfonimidoylbenzamides of general formula (S) used as herbizides. In said formula (I), R, R', R", X, W and Z represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals su...
|
|
WO/2013/124238A1 |
The invention relates to sulfinyl aminobenzamides of general formula (I) acting as herbicides. In formula (I), R, R', R", X, W and Z represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen. Q rep...
|
|
WO/2013/124245A1 |
The invention relates to 4-nitro-substituted N-(tetrazol-5-yl)-, N-(triazol-5-yl)-, and N-(1,3,4-oxadiazol-2-yl)aryl carboxylic acid amides of the general formula (I) as herbicides. In the formula (I), X, Y, and W represent groups such a...
|
|
WO/2013/122028A1 |
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...
|
|
WO/2013/108800A1 |
Provided are: a compound having an excellent hypoglycemic activity and an excellent protective activity for a β cell or the pancreas, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition having an excellent th...
|
|
WO/2013/098146A1 |
The present invention relates to 3-[(1,3-thiazol-4-ylmethoxyimino)(phenyl)methyl]-2-substitut
ed- 1,2,4-oxadiazol-5(2H)-one derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in t...
|
|
WO/2013/087577A1 |
The invention relates to N-(1,2,5-oxadiazol-3-yl), N-(1,3,4-oxadiazol-2-yl), N-(tetrazol-5-yl), and N-(triazol-5-yl) aryl carboxylic acid amides of general formula (I) as herbicides. In said formula (I), R, V, X, Y, and Z stand for group...
|
|
WO/2013/090454A2 |
The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of ...
|
|
WO/2013/078123A1 |
The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases us...
|
|
WO/2013/075199A1 |
The present invention relates to acyl-hydrazone compounds, in particular 3,4,5-trimethoxyphenyl-hydrazide derivatives, as well as the oxadiazole analogs thereof and other similar compounds, and to the pharmaceutical use of the same for t...
|
|
WO/2013/071693A1 |
Provided are an anti-Coxsackie virus oxadiazole compound as represented by formula (I), or a pharmaceutically acceptable salt thereof, a preparation method, and a pharmaceutical composition and use thereof, wherein R is CH3 or CF3; R' an...
|
|
WO/2013/072300A1 |
The present invention relates to substituted 1,2,5-oxadiazole compounds of the formula I and the N-oxidesand salts thereof and to compositions comprising the same. The invention also relates to the use of the 1,2,5-oxadiazole compounds o...
|
|
WO/2013/067578A1 |
Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated card...
|
|
WO/2013/064459A1 |
The invention relates to oxime-ether-substituted benzoylamides of general formula (I) as herbicides. In said formula (I), R, X, and Y stand for groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen. Q st...
|
|
WO/2013/064714A1 |
The invention relates to compounds with amino benzooxadiazolyl structure which are capable of inhibiting the activation or the biological activity of mitogen-activated protein kinase (MAPK) p38 and the use thereof in the treatment of a d...
|
|
WO/2013/066833A1 |
The invention relates to compounds that inhibit histone deacetylase (HDAC) enzymes, the preparation of these compounds, the use of these compounds in the treatment of diseases or conditions ameliorated by inhibition of HDAC activity, and...
|
|
WO/2013/057372A1 |
This invention relates to novel 4,5-dihydroisoxazoles and 4,5-dihydro[1,2,4]-oxadiazoles of formula (I), to their use as androgenic or antiandrogenic agents or androgen receptor modulators, and to methods of their preparation.
|
|
WO/2013/049119A1 |
The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatm...
|
|
WO/2013/039187A1 |
[Problem] To provide a compound useful as a renal disease preventive and/or therapeutic agent. [Solution] The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoi...
|
|
WO/2013/037717A1 |
The present invention provides fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1
,2,4-oxadiazol-5(4H)-one derivatives of formula (I) wherein A represents a pyridyl or thiazole group and X1, Y1 to Y5 represent indepe...
|
|
WO/2013/036530A1 |
The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2013/024843A1 |
[Problem] To provide a means for selective fluorescent labeling of the Golgi apparatus, the means offering low cytotoxicity and excellent intracellular stability. [Solution] According to the present invention, provided are a ceramide der...
|
|
WO/2013/014204A2 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/008162A1 |
The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions there...
|
|
WO/2013/000395A1 |
Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof; the inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, imm...
|
|
WO/2012/176856A2 |
To provide a novel pesticide. The present invention provides a compound represented by the formula (I) or its salt, and a pesticide containing it as an active ingredient: (I) wherein each of R1 and R2 is a hydrogen atom, a halogen atom, ...
|
|
WO/2012/162635A1 |
Compounds that modulate GluR5 activity and methods of using the same are disclosed.
|
|
WO/2012/147764A1 |
Provided is a novel compound having NPY Y5 receptor antagonistic activity. It was discovered that a compound represented by (1) (where R1 is an optionally substituted alkyl and the like; p, q, and r are each independently 0 or 1; ring A ...
|
|
WO/2012/142671A1 |
The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of th...
|
|
WO/2012/145361A1 |
The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical a...
|
|
WO/2012/129564A2 |
Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiet...
|
|
WO/2012/126932A1 |
N-(1,3,4-Oxadiazol-2-yl)arylcarboxamides of the general formula (I) are described as herbicides. In this formula (I), A is nitrogen or CY. R, X, Y and Z are each radicals such as hydrogen, organic radicals such as alkyl, and other radica...
|
|
WO/2012/123420A1 |
Herbicide safener compositions are described which comprise active ingredients from the group of the N-(1,2,5-oxadiazol-3-yl)benzamides and also safeners. These herbicidal compositions are especially suitable for use against weed plants ...
|
|
WO/2012/125832A2 |
The present invention relates to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to substituted aromatic compounds useful as therapeutic agents.
|
|
WO/2012/120398A1 |
The invention provides a compound of the formula (I): wherein A, R1, R2 and R3 are as defined herein, or a pharmaceutically acceptable salt thereof. Such compounds are small molecule TRPM8 blockers and therefore useful in the propylaxis ...
|
|
WO/2012/121168A1 |
The purpose of the present invention is to provide: a novel compound having an excellent CK2-inhibiting activity and high safety; and use applications of the compound. Provided are: a CK2 inhibitor comprising, as an active ingredient, a ...
|
|
WO/2012/116151A2 |
Compounds of formula II are described, wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis...
|
|
WO/2012/110833A2 |
The present invention relates to fluorescence lifetime modulators, conjugates comprising fluorescence lifetime modulators moieties and methods of making them. The present invention further relates to the use of the fluorescence lifetime ...
|
|
WO/2012/112841A2 |
The present invention relates to salts and crystalline forms of [1,2,4]oxadiazol-3-yl]-phenoxy}-cycloalkyl carboxylic acids, processes for their preparation, pharmaceutical compositions comprising such compounds, and methods of using them.
|
|
WO/2012/082853A1 |
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In an...
|
|
WO/2012/080705A1 |
An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hCE-1 in the cells independently of the amount of hCE-2 and/or hCE-3 in the cells, said imaging agent being a covalent conjugate of (...
|
|
WO/2012/074732A1 |
The present invention relates to novel phenyl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2012/074730A1 |
The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
